April 07, 2021—Click Therapeutics Expands its Leadership with Executive and Board Appointments
April 7, 2021—Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials.
March 25, 2021—Evidation Raises $153M to Scale Virtual Health Capabilities of Achievement™ Platform.
March 21, 2021—LAVA Therapeutics Announces Pricing of Initial Public Offering .
March 17, 2021—Amathus Therapeutics signs strategic collaboration with Merck to Develop Treatments for Neurodegenerative Diseases.
March 15, 2021—LAVA Therapeutics Appoints Edward F. Smith as Chief Financial Officer.
February 25, 2021—Medisafe Secures $30M in Series C Funding led by Sanofi Ventures and ALIVE Israel HealthTech Fund to Build Future Model of Patient Support.
February 24, 2021—Otsuka and Click Therapeutics Initiate First-of-its-Kind Fully Remote Clinical Trial Using Digital Therapeutics as Adjunctive Therapy in Adults With Major Depressive Disorder.
February 22, 2021—Lava Therapeutics appoints Dr. Kapil Dhingra as Chairman of the Board of Directors in Advance of Lead Program Entering the Clinic.
February 10, 2021—i2O Therapeutics, developers of a platform for oral delivery of traditionally injectable biological drugs, announced today a research collaboration with Sanofi to investigate the oral delivery of Sanofi's Nanobody®-based medicines, which are currently administered through intravenous or subcutaneous injections.
December 15, 2020—Minervax raises upsized EUR 47.4M Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials
December 15, 2020—NodThera Appoints Chief Medical Officer and Chief Financial Officer
October 30, 2020—Icosavax Launches COVID-19 Vaccine Program with Preclinical Data and $16.5 Million in New Funding
October 29, 2020—Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis
September 17, 2020—Lava Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs
September 14, 2020—Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Trial of EP547, a MRGPR-targeted Therapy to Treat Cholestatic and Uremic Pruritis
September 11, 2020—Click Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
August 21, 2020—Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering
August 20, 2020—Science 37 Raises $40 Million to Extend its Leadership in the Decentralized Clinical Trial Market
July 21, 2020—MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies
July 20, 2020—HealthVerity Acquires Curisium to Enhance Data Exchange for Drug Rebate Processing and Contract Management
July 9, 2020—Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients
July 1, 2020—Evidation Raises $45 Million Series D, Hires CCO To Accelerate Commercial Momentum and Expand Into Virtual Health
June 10, 2020—Fulcrum Therapeutics Completes $68.5 Million Private Placement
June 5, 2020— Evidation Health and BARDA Partner on Early Warning System for COVID-19
June 3, 2020— NodThera a clinical stage biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat diseases driven by chronic inflammation, today announced that it has secured $55 million (£44
million) in a Series B financing
May 27, 2020—Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity
April 9, 2020—i2O Therapeutics, an innovative biotech company developing a platform for oral delivery of traditionally injectable biological drugs, announced today it has raised a $4 million seed funding round led by Sanofi Ventures and JDRF T1D Fund.
November 19, 2019 - Sanofi and Aetion launch enterprise-wide collaboration to advance regulatory submissions using real-world evidence
October 7, 2019 -Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease
October 3, 2019 -Icosavax Launches with $51 Million Series A Financing to Advance Computationally Designed VLP Vaccines
September 6, 2019 -Click Therapeutics Announces Appointment of Top Ranked Healthcare Research Analyst Ross J. Muken as Chief Financial Officer
September 5, 2019 - Sanofi Ventures co-leads investment in Veralox Therapeutics to enable further develop first-in-class 12-LOX inhibitors for Heparin-Induced Thrombocytopenia and Thrombosis, Type 1 Diabetes, and other indications
July 10, 2019 - Yumanity Therapeutics Appoints Richard Peters, M.D., Ph.D., as Chief Executive Officer
June 27, 2019 - Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome;
Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020
June 26, 2019 -Omada Health Raises $73 Million to Accelerate Program Expansion
Digital Care Leader’s Integrated Program Supports Individuals Dealing with Chronic
Disease, Mental Health Issues
May 15, 2019 -Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases.
April 10 2019 - Inozyme Pharma, a biotechnology company developing novel medicines to treat rare, debilitating, and life-threatening mineralization disorders, today announced that the Company raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments. Cross-over investors, including RA Capital Management, Cowen Healthcare Investments, and Rock Springs Capital, as well as the Company’s previous investors, Longitude Capital, NEA, Novo Holdings, and Sanofi Ventures, also joined this round.
February 5 2019 - Aetion, the health care technology company that delivers the real-world analytics and evidence platform needed to engage in value-based care, announced today a $27 Million Strategic Investment backed by Global Health Care Leaders
January 24 2019 - Navitor Pharmaceuticals Commences Phase 1 Clinical Evaluation of NV-5138, a Novel mTORC1 Activator in Patients with Treatment-Resistant Depression
January 3 2019 - Click Therapeutics, Inc. and Otsuka America, Inc., announce today that the companies have signed a collaboration agreement to develop and commercialize a prescription digital therapeutic for treatment of Major Depressive Disorder